Cyltezo Safety in Elderly Patients
Cyltezo (adalimumab-adbm) can be used in elderly patients, but requires heightened vigilance due to significantly increased risks of serious infections and malignancies compared to younger adults. The FDA label explicitly states that among patients ≥65 years, the frequency of serious infection and malignancy was higher than in those <65 years 1.
Key Safety Considerations
Infection Risk - The Primary Concern
Elderly patients face substantially elevated infection risk, with up to a 20-fold increase in severe infections when treated with adalimumab products 2. The most critical factors include:
- Age thresholds: Risk increases at ages 45,50, and particularly ≥65 years, with patients >65 years showing severe infection rates of 11% versus 0.5% in younger patients 2
- Combination therapy dramatically amplifies risk: Odds ratio increases from 2.9 for monotherapy to 14.5 for combination with thiopurines and/or steroids 2
- Specific infection patterns: Fungal and mycobacterial infections are particularly associated with anti-TNF agents like adalimumab 2
Malignancy Risk
The FDA label mandates close monitoring for malignancy development in elderly patients 1. Current evidence shows:
- Increased risk of non-melanoma skin cancers and lymphoma, particularly with thiopurine combination therapy 3
- Skin cancer risk: NMSC hazard ratio 1.7 (95% CI 1.3-2.2) and melanoma 2.6 (95% CI 1.0-6.7) with infliximab (similar class) 4
Clinical Decision Framework
When to Use Cyltezo in Elderly Patients
Consider adalimumab when:
- Disease severity warrants biologic therapy despite age-related risks
- Patient has no active infections or recent serious infections
- Tuberculosis screening is negative (or latent TB adequately treated)
- Comorbidities are optimized
- Patient can be monitored closely for infection signs
When to Choose Alternative Therapies
Prioritize gut-selective biologics (vedolizumab) or IL-12/23 inhibitors (ustekinumab) in elderly patients when clinically appropriate, as these show lower systemic infection risk 5, 2, 3. The 2021 ECCO guidelines specifically note vedolizumab's trend toward lower non-gastrointestinal infections 2.
For elderly patients >60 years in sustained remission on thiopurines, consider stopping after discussion with the IBD team 5, which would eliminate the need for high-risk combination therapy if adalimumab is being considered.
Mandatory Monitoring Protocol
Pre-Treatment Assessment
- Tuberculin skin test and chest X-ray (consider ≥5mm induration positive even with prior BCG) 6, 1
- Hepatitis B serology 6
- Assessment for endemic fungal exposure (histoplasmosis, coccidioidomycosis, blastomycosis) 6, 1
- Comprehensive comorbidity evaluation 3
During Treatment
- Temperature monitoring: Instruct patients to check frequently and report fever immediately 6
- Monthly clinical assessment for infection signs: cough, fever, chills, wound infections, urinary symptoms, respiratory changes 6
- Close monitoring for new infections, particularly in first year when hazard is highest 7
- Vigilance for atypical presentations of tuberculosis and opportunistic infections 1
Common Pitfalls to Avoid
Underestimating combination therapy risk: The combination of adalimumab with corticosteroids and/or thiopurines creates multiplicative rather than additive infection risk in elderly patients 2
Inadequate TB screening: False-negative tuberculin tests can occur; maintain high clinical suspicion even with negative screening 1
Ignoring functional status: Chronologic age alone is insufficient—assess frailty, comorbidities, and functional status 3
Delayed infection recognition: Elderly patients may present with atypical infection symptoms; maintain low threshold for evaluation 1
Efficacy Considerations
Efficacy appears preserved in elderly patients 1. Recent 2025 data in rheumatoid arthritis showed sustained 24-month efficacy in patients ≥60 years, though those with high baseline inflammatory burden (DAS28-CRP ≥5.1, ESR ≥40 mm/h) had poorer outcomes 8. A 2021 uveitis study demonstrated significant improvements in elderly patients ≥60 years with acceptable adverse event rates of 26.8% 9.
Bottom Line
The decision to use Cyltezo in elderly patients requires explicit risk-benefit discussion prioritizing infection and malignancy surveillance over convenience. When disease severity justifies biologic therapy, adalimumab can be effective, but alternative biologics with more favorable safety profiles in the elderly (vedolizumab, ustekinumab) should be strongly considered first 5, 2, 3. If adalimumab is chosen, avoid combination immunosuppression when possible, ensure rigorous pre-treatment screening, and maintain intensive monitoring throughout treatment.